سعر اوكساليبلاتين ابيو 50 مجم فيال 2025

Oxaliplatin Ebewe 50 mg vial: oxaliplatin 50 mg concentrate/solution for intravenous infusion (vial) by Ebewe (Novartis Pharma, Sandoz division, Egypt); pack: 1 vial (50 mg oxaliplatin). Antineoplastic.

• In combination with infusional fluorouracil and leucovorin: adjuvant treatment of stage III colon cancer after complete resection of the primary tumour.Population: AdultsDailyMed (U.S. National Library of Medicine)
• In combination with infusional fluorouracil and leucovorin: treatment of advanced colorectal cancer.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>= 40%): peripheral sensory neuropathy, neutropenia, thrombocytopenia, anaemia, nausea, increased transaminases and alkaline phosphatase, diarrhoea, fatigue, emesis and stomatitis.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity reaction to oxaliplatin or other platinum-based drugs (reactions have included anaphylaxis).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: serious and fatal hypersensitivity reactions including anaphylaxis can occur within minutes and in any cycle; discontinue permanently.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Acute and delayed peripheral sensory neuropathy (avoid topical ice); severe myelosuppression (delay until neutrophils >= 1.5 x10^9/L and platelets >= 75 x10^9/L); PRES; pulmonary toxicity; hepatotoxicity; QT prolongation/ventricular arrhythmias; rhabdomyolysis; haemorrhage; embryo-fetal toxicity.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• QT-prolonging medicinesAvoid co-administration with drugs known to prolong the QT interval.DailyMed (U.S. National Library of Medicine)
• Nephrotoxic medicinesClearance of platinum species may decrease; avoid co-administration with nephrotoxic drugs.DailyMed (U.S. National Library of Medicine)
• Anticoagulants (e.g., warfarin)Prolonged PT/INR, occasionally with haemorrhage, reported with oxaliplatin plus fluorouracil/leucovorin; monitor more frequently.DailyMed (U.S. National Library of Medicine)

• Based on its interaction with DNA, oxaliplatin can cause fetal harm; human data do not establish presence or absence of risk; adverse embryo-fetal effects in rats below human dose. Verify pregnancy status; females use effective contraception during and for 9 months after the final dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in milk; advise not to breastfeed during treatment and for 3 months after the final dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Oxaliplatin: Undergoes non-enzymatic conversion to reactive DACH-platinum species that form inter- and intrastrand platinum-DNA crosslinks, inhibiting DNA replication and transcription; cytotoxicity is cell-cycle nonspecific (US label 12.1).